Table 1 BsAbs against cancers in clinical development
From: The development of bispecific antibodies and their applications in tumor immune escape
Molecule | Targets | Format | MOAa | Indication | Statusb | Developed by |
|---|---|---|---|---|---|---|
Catumaxomab | CD3 + EpCAM | TrioMab | T cell recruitment | Malignant ascites Gastric cancer Ovary cancer Epithelial cancer | Market 2 2 1-2 | Fresenius Biotech |
FBTA05 | CD3 + CD20 | TrioMab | T cell recruitment | BCL | 1-2 | Fresenius Biotech |
Ertumaxomab | CD3 + Her2 | TrioMab | T cell recruitment | Metastatic breast cancer | 2 | Fresenius Biotech |
Blinatumomab (MT103) | CD3 + CD19 | BiTE | T cell recruitment | B-ALL Relapsed/refractory ALL Pediatric ALL Relapsed NHL | Market 2 1–2 1 | Amgen |
MT110 | CD3 + EpCAM | BiTE | T cell recruitment | Colorectal cancer Lung and gastrointestinal cancer | 1 1 | Amgen |
MT111 | CD3 + CEA | BiTE | T cell recruitment | Gastric cancer advanced adenocarcinoma | 1b | Amgen |
AMG330 | CD3 + CD33 | BiTE | T cell recruitment | Relapsed/refractory AML | 1 | Amgen |
MT112 | CD3 + PSMA | BiTE | T cell recruitment | Prostate cancer | 1 | Bayer |
RG7221 | Angiopoietin 2 + VEGF | CrossMab | Two-ligand inactivation | Colorectal cancer | 2 | Roche |
RG7597 | Her1 + Her3 | DAF-IgG | Two-RTK inactivation | Head and neck cancer, colorectal cancer | 2 | Genentech |
MM111 | Her2 + Her3 | scFv-HSA | Two-RTK inactivation | Advanced gastric and esophageal cancer | 2 | Merrimack |
MM141 | IGF1R + Her3 | scFv-IgG | Two-RTK inactivation | Advanced solid tumors | 1 | Merrimack |
MGD006 | CD3 + CD123 | DART | T cell recruitment | AML | 1 | Macrogenics and Servier |
MGD007 | CD3 + GPA33 | DART-Fc | T cell recruitment | Colorectal cancer | 1 | Macrogenics and Servier |
AFM11 | CD3 + CD19 | TandAb | T cell recruitment | Non-Hodgkin’s lymphoma | 1 | Affimed |
AFM13 | CD30 + CD16 | TandAb | NK cell recruitment | Hodgkin’s disease | 1 | Affimed |
LY3164530 | Her1 + cMET | orthoFab-IgG | Two-RTK inactivation | Solid tumors | 1 | Eli Lilly |
TF2 | CEA + hapten | D&L Fab3 | Payload delivery | Colorectal cancer | 1 | Immunomedics |